Overview

Combination therapy, the association of an anti-Tumor Necrosis Factor (TNF) to an immunosuppressant, is recognized as the most effective treatment during Crohn's disease (CD). Several mechanisms have been proposed to explain the superiority of combination therapy over monotherapy, the additive effect of two effective drugs or the prevention of anti-TNF immunogenicity. As the best combination therapy is unknown, both azathioprine (AZA) and methotrexate (MTX) are used. Some retrospective studies suggest a higher effectiveness of AZA. MTX may have an advantage in terms of safety.

The investigators hypothesize that AZA is more effective than MTX as combination therapy with adalimumab to improve short-term endoscopic, clinical and pharmacological outcomes in CD patients.

Eligibility

Inclusion Criteria:

• Male or female patients with age > 18 years
• Crohn's disease for at least 6 weeks,
• Clinically active with CDAI > 150
• Active inflammation by endoscopy (CDEIS > 4) at baseline
• Not responder to conventional therapy or are intolerant to or have medical contraindications for such therapies and initiating treatment with adalimumab
• Patient followed in a center belonging to the GETAID network
• Fertile men and women of childbearing potential included in the protocol should use adequate methods of contraception according to study drug SMPCs.
• Written consent

Exclusion Criteria:

• Short bowel syndrome, ostomy, symptomatic stricture, abscess, recent history of abdominal surgery (<3 months)
• Non-passable colonic stricture
• Previous intolerance to thiopurines or MTX
• Previous exposition to adalimumab
• Contra-indication to immunosuppressants or anti-TNF
• Others serious simultaneous illness that could interfere with study participation
• Planning pregnancy, pregnancy or lactation or absence of contraception
• Known substance abusers
• Use of any investigational drug within 30 days
• Adults protected by law